Thymosin Beta-4
What the Research Actually Shows
Human: 7 studies, 3 groups · Animal: 5 studies, 5 groups · In Vitro: 3
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
Thymosin Beta-4: The Body’s Own Repair Signal — and Why the 43-Amino-Acid Original Isn’t the Same as the Fragment You’ve Heard About
BLUF: Bottom Line Up Front
Thymosin beta-4 is a small protein your body already makes in large amounts. It helps cells move, reduces swelling, and plays a role in healing wounds and protecting the heart. Eye drops made from it (RGN-259) have been tested in Phase II and Phase III human trials for dry eye and corneal injuries. A 2025 clinical trial in 96 heart attack patients showed it may help reduce damage when given early. It is not the same molecule as TB-500 — that is a shorter fragment with a different research history and different evidence.
Thymosin beta-4 is one of the most abundant proteins inside human cells. It was first isolated from calf thymus tissue in 1981, and researchers initially studied it for its role in the immune system. Over the following decades, it became clear that Tβ4 does far more than modulate immunity. It helps cells move, builds new blood vessels, and dials down inflammation across multiple tissue types.
What makes Tβ4 editorially distinctive is its split identity. The full 43-amino-acid parent molecule has real clinical trial data. There are Phase II and Phase III trials for dry eye and corneal healing, a Phase I safety study in healthy volunteers given IV Tβ4, a pilot study of Tβ4-treated stem cell transplantation in heart attack patients, and a 2025 trial in 96 patients after major heart attacks. That portfolio is thin but real. TB-500 — the synthetic fragment made from just seven of those amino acids — has zero controlled human trials. The biohacking community frequently treats them as the same compound. This article explains why they are not.
This is also a compound where the delivery method is an evidence boundary. Eye drop data does not validate injection claims. Hospital IV data does not validate at-home self-injection. Every claim in this article is judged against the specific delivery method and formulation that produced the evidence.
Table of Contents
Quick Facts: Thymosin Beta-4 at a Glance
TYPE
Endogenous protein / Naturally occurring peptide
GENERIC NAME
Timbetasin (INN) / Thymosin beta-4
PRIMARY CLASS
Actin-sequestering protein with multi-system repair signaling
RESEARCH STATUS
Phase II/III clinical trials (ophthalmic); Phase I–II (cardiac); extensive preclinical
ENDOGENOUS ORIGIN
Present in virtually all nucleated human cells; highest concentrations in platelets, white blood cells, and wound fluid
MOLECULAR WEIGHT
4,921 Da (43 amino acids, N-terminally acetylated)
PRIMARY MOLECULAR FUNCTION
Sequesters monomeric G-actin to regulate cytoskeletal dynamics, cell migration, and tissue repair signaling
SEQUENCE
Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
CLINICAL PROGRAMS
RGN-259 (0.1% ophthalmic solution for dry eye/NK); IV rhTβ4 (cardiac — NCT05485818); Tβ4-pretreated EPC transplantation (cardiac pilot)
ROUTE (CLINICAL)
Topical ophthalmic (eye drops); Intravenous (cardiac trials); No published clinical data for subcutaneous injection
EVIDENCE TIER
HALF-LIFE
IV pharmacokinetics show dose-proportional response with increasing half-life at higher doses (Phase I). Exact systemic half-life values from PMID: 20536472.
STORAGE
Lyophilized: –20°C long-term, 2–8°C short-term. Reconstituted: 2–8°C, use within 21–28 days. Avoid repeated freeze-thaw cycles.
FDA STATUS
Not approved for any indication. Category 2 bulk drug substance (compounding restricted). RGN-259 in clinical development. Potential reclassification pending per February 2026 HHS announcement.
WADA STATUS
Prohibited at all times (S2.3 — Growth Factors). Listed since 2018 as non-Specified Substance. Applies to both Tβ4 and derivatives including TB-500.
LEGAL STATUS
Available as research chemical. Not approved for human therapeutic use. Compounding pharmacies restricted under FDA Category 2 designation.
COMMUNITY INTEREST
Very high. Tβ4/TB-500 is among the most-discussed tissue repair peptides. The “Wolverine stack” (Tβ4 + BPC-157) is a staple of biohacking forums — with zero published evidence for the combination.
VERDICT
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Thymosin Beta-4?
Thymosin beta-4 is a 43-amino-acid protein that belongs to the beta-thymosin family of actin-sequestering molecules. It was first isolated in 1981 from bovine thymus extract — the same tissue preparation that yielded thymosin alpha-1, which went on to become an approved drug (Zadaxin) for hepatitis B in several countries. Tβ4 took a different path. While thymosin alpha-1 found its niche in immunology, Tβ4 emerged as something more fundamental: a master regulator of the cellular machinery that controls how cells move, divide, and repair damaged tissue.
The protein is found in virtually every nucleated cell in the human body. It is not a rare signaling molecule operating at the margins — it is one of the most abundant intracellular peptides in mammalian biology. Platelets release it at wound sites. White blood cells carry it to areas of inflammation. Its concentration in wound fluid is measurably elevated compared to healthy tissue, suggesting the body actively deploys Tβ4 as part of its natural repair response.
The name “thymosin” is something of a historical accident. When Allan Goldstein’s laboratory at George Washington University first isolated thymic peptides in the 1960s and 1970s, they grouped all thymus-derived molecules under the “thymosin” umbrella. It later became clear that Tβ4 and thymosin alpha-1 are structurally and functionally unrelated — they share a name the way two unrelated people might share a surname. Tβ4 is not primarily an immune modulator. It is primarily an actin-binding protein with downstream effects on cell migration, angiogenesis, and inflammation.
PLAIN ENGLISH
Thymosin beta-4 is a small protein found inside nearly every cell in your body. It was discovered in the 1980s and initially thought to be part of the immune system. Scientists later learned its main job is helping cells move and repair damaged tissue. Your body floods wound sites with it naturally — it’s part of the built-in healing toolkit.
Tβ4 vs. TB-500: Why the Distinction Matters
This is the single most important editorial distinction in this article, and it is one the biohacking community consistently gets wrong.
Thymosin beta-4 is a 43-amino-acid protein. TB-500 is a synthetic peptide fragment corresponding to the active region of Tβ4 — specifically, the sequence centered around residues 17–23 (the Ac-SDKP region and adjacent actin-binding domain). TB-500 is not Tβ4 with a different name. It is a shorter molecule with a different molecular weight, a different three-dimensional structure, a different pharmacokinetic profile, and — critically — a different evidence base.
What the full-length protein (Tβ4) has that the fragment (TB-500) does not: Phase II and Phase III clinical trials in humans (RGN-259 for dry eye and neurotrophic keratopathy); a Phase I IV safety study in healthy volunteers (PMID: 20536472); a 2016 pilot study of Tβ4-pretreated endothelial progenitor cell transplantation in STEMI patients (PMID: 27288307); a 2025 randomized, placebo-controlled cardiac trial in 96 STEMI patients; and a Phase I safety study in healthy Chinese volunteers (PMID: 34346165).
What TB-500 has: Extensive preclinical data (wound healing, cardiac repair, corneal healing — all in animal models). Zero controlled human trials.
When someone online says “TB-500 has clinical trials,” they are almost always citing Tβ4 studies. The pharmacological implication is that Tβ4 retains structural features — its full three-dimensional folding, its complete set of receptor-binding domains — that the truncated fragment does not. Whether those additional features matter clinically is an open question. What is not open is the factual distinction: studies conducted with full-length Tβ4 cannot be cited as evidence for a shorter synthetic fragment.
PLAIN ENGLISH
TB-500 is a piece of thymosin beta-4, not a different name for it. The full-length protein has been tested in human clinical trials. The fragment has not. When you see “TB-500 clinical trials,” check the fine print — those trials almost certainly used the full protein, not the fragment.
Mechanism of Action
Tβ4’s primary intracellular function is the sequestration of monomeric globular actin (G-actin). Actin is the most abundant protein in eukaryotic cells and the structural backbone of the cytoskeleton. Tβ4 binds G-actin in a 1:1 complex, preventing it from polymerizing into filamentous actin (F-actin). This creates a reservoir of available actin monomers that cells can rapidly deploy when they need to move, divide, or change shape.
During injury, actin dynamics become the rate-limiting step in tissue repair. Cells at a wound edge must physically migrate into the gap. Endothelial cells must sprout into new blood vessels. Immune cells must navigate to the site of damage. All of these processes require rapid, coordinated changes in the actin cytoskeleton — and Tβ4 regulates the supply of raw material.
Cell Migration
By modulating actin availability, Tβ4 promotes the directional movement of keratinocytes, endothelial cells, and cardiac progenitor cells. In wound models, exogenous Tβ4 accelerates the migration of cells into the wound bed.
Angiogenesis
Tβ4 stimulates the formation of new blood vessels. The actin-binding domain (residues 17–23) is specifically implicated. In post-MI animal models, Tβ4 administration increased vessel density in infarcted tissue (PMID: 17600280).
Anti-Inflammatory Signaling
Tβ4 suppresses NF-κB activation and reduces pro-inflammatory cytokines including TNF-α and IL-6. In a septic shock model, Tβ4 reduced mortality by 50% (PMID: 12860178).
Anti-Fibrotic Effects
In cardiac and hepatic models, Tβ4 prevents excessive collagen deposition. It downregulates α-smooth muscle actin and modulates TGF-β signaling (PMID: 35712678).
Progenitor Cell Activation
Tβ4 activates epicardium-derived progenitor cells through the integrin-linked kinase and Akt signaling pathways. A 2012 study clarified an important nuance: Tβ4 does not reprogram epicardial cells into cardiomyocytes. Its cardiac benefit operates through progenitor activation and angiogenesis, not direct muscle regeneration (PMID: 21907210).
PLAIN ENGLISH
Tβ4’s core job is controlling actin — the protein that acts as the cell’s internal skeleton and movement engine. When tissue is damaged, cells need to move fast to close the wound, build new blood vessels, and clean up inflammation. Tβ4 makes the raw building materials available. It also turns down the inflammatory alarm and prevents excessive scarring. Think of it as a logistics coordinator at a disaster site — it doesn’t do the rebuilding itself, but it makes sure the workers have what they need.
Clinical Evidence in Humans
Ophthalmic Trials (RGN-259)
Phase II — Dry Eye Disease (PMID: 26056426): A randomized, placebo-controlled trial showed 27% reduction in ocular discomfort scores and significant improvements in corneal fluorescein staining. Well tolerated with no significant adverse events.
Phase II — Severe Dry Eye / GVHD (PMID: 25826322): Significant improvements in tear volume and epithelial barrier function in treatment-resistant dry eye associated with graft-versus-host disease.
Phase III — Neurotrophic Keratopathy, SEER-1 (PMID: 36518890): Complete corneal healing in 6 of 10 RGN-259-treated subjects versus 1 of 8 placebo (p = 0.0656). Primary endpoint narrowly missed significance; secondary endpoints showed significant healing improvements. Safety was excellent.
Phase III — Dry Eye, SEER-3: Missed primary endpoint (stronger-than-expected placebo response). A US Phase III trial is ongoing.
Cardiac Trials
Phase I — IV Safety (PMID: 20536472): Doses from 42 to 1,260 mg IV over 14 days in healthy volunteers. No dose-limiting toxicity. Dose-proportional pharmacokinetics with increasing half-life at higher doses.
Phase I — Healthy Chinese Volunteers (PMID: 34346165): Recombinant human Tβ4 was safe and well tolerated.
Pilot — Tβ4-Pretreated EPC Transplantation in STEMI (PMID: 27288307): Feasible and safe, with potentially beneficial effects on exercise capacity and left ventricular function.
RCT — rhTβ4 in 96 STEMI Patients (Cardiovascular Research, 2025): Positive signal in a subgroup but overall primary endpoint did not reach statistical significance. This pattern — positive subgroup, non-significant full cohort — is common in early cardiac trials and typically warrants a larger confirmatory study.
What Human Evidence Does Not Exist
No controlled human trial has tested Tβ4 for: musculoskeletal injury repair, neurological injury, subcutaneous injection for any indication, hair growth, or anti-aging applications. These are the applications that dominate online discussions.
PLAIN ENGLISH
The topical eye drop evidence is real: multiple controlled trials showing corneal healing. The cardiac evidence is early but promising: safety confirmed at high doses, one real RCT with a directional signal. For everything people actually want to use Tβ4 for — tendon repair, muscle healing, anti-aging — there are zero human trials.
Preclinical Research
The preclinical portfolio for Tβ4 is extensive and spans cardiac repair, wound healing, corneal regeneration, neuroprotection, liver protection, and lung fibrosis.
Cardiac Repair
A landmark 2010 study (PMID: 20536454) established Tβ4 as the first known molecule to simultaneously inhibit cardiomyocyte death, stimulate angiogenesis, and activate endogenous cardiac progenitor cells. Subsequent studies confirmed reduced infarct size, decreased apoptosis, and preserved ejection fraction (PMID: 17600280; PMID: 24348421; PMID: 35712678).
Wound Healing and Corneal Repair
Topical Tβ4 accelerated wound closure in multiple animal models. Corneal studies showed accelerated re-epithelialization and decreased inflammatory markers (PMID: 11950239).
Anti-Inflammatory and Anti-Fibrotic
Reduced mortality by 50% in rodent septic shock. Limited autophagy-mediated inflammation (PMID: 30063848). Protected against liver injury by suppressing NF-κB (PMID: 30116499). Prevented pulmonary fibrosis (PMID: 34414534).
PLAIN ENGLISH
In animal studies, Tβ4 has been tested across nearly every major tissue system — heart, skin, eyes, brain, liver, lungs. The results are consistently positive: less damage, faster healing, less scarring. But these are animal results. They tell us the biology is plausible. They do not tell us what happens in humans at the doses and routes people actually use.
The Cancer Question
Tβ4’s relationship with cancer is genuinely complex, and any honest article must address it directly.
The concern: Tβ4 promotes cell migration, angiogenesis, and cell survival — three processes that tumors also exploit. A 2003 Cancer Metastasis Reviews paper (PMID: 14625258) documented potential pro-metastatic effects in tumor models.
The counter-evidence: A study in Haematologica found tumor-suppressive effects in multiple myeloma. A 2023 study found exogenous Tβ4 suppressed IPF-associated lung cancer in mice.
The honest assessment: The evidence does not support a simple narrative. A protein which promotes cell migration and angiogenesis will behave differently in healthy tissue and in a tumor microenvironment. Clinical trials have not reported cancer-related adverse events, but they are short-duration and small-sample. Individuals with active malignancies should not use Tβ4 outside of clinical trials.
PLAIN ENGLISH
Most tissue repair peptides raise cancer questions. Tβ4’s data is genuinely mixed — some studies suggest it could help tumors spread, others suggest it suppresses them. The short-term clinical trials haven’t flagged cancer issues, but they weren’t designed to detect them. If you have active cancer, don’t use this without medical supervision.
Claims vs. Evidence
| Claim | What the Evidence Actually Shows | Verdict |
|---|---|---|
| Heals tendons and ligaments | No human trial. Animal models show enhanced cell migration. All evidence preclinical. | Preclinical only |
| Repairs cardiac damage | One RCT (n=96, 2025) showed positive subgroup signal but missed overall primary endpoint. Mechanism is vascular repair, not direct cardiomyocyte regeneration. | Early clinical signal |
| Heals corneal injuries | Phase II and Phase III trials (RGN-259) show consistent benefit. SEER-1: 60% vs 12.5% complete healing. SEER-3 missed primary endpoint. | Moderate clinical evidence |
| Reduces inflammation | Preclinical data strong (NF-κB suppression, cytokine reduction). No human anti-inflammatory trial. | Preclinical only |
| Promotes hair growth | One rodent study showed follicle development. No human hair growth trial. | Single preclinical study |
| Identical to TB-500 | Structurally and pharmacologically distinct. Tβ4 is 43 amino acids; TB-500 is a 7–17 amino acid fragment. Different evidence bases. | Incorrect |
| Prevents aging | A 2022 review discusses theoretical anti-aging potential. No human anti-aging trial. Correlation ≠ therapeutic opportunity. | Theoretical |
| Safe for long-term use | Short-term safety excellent (up to 14 days IV, several weeks ophthalmic). No long-term data. Cancer question unresolved. | Short-term data only |
| Heals all wounds faster | Ophthalmic evidence supports corneal healing. Dermal and musculoskeletal evidence is animal-only. Route and tissue type matter. | Depends on tissue and route |
| Protects the brain | Animal models show neuroprotective effects. No human neurological trial. | Preclinical only |
| Better than BPC-157 | No head-to-head comparison exists. Different mechanisms, different tissue specificities. | No basis for comparison |
| FDA-approved in other countries | Not approved by any major regulatory agency. Thymosin alpha-1 (a different molecule) is approved in some countries — not Tβ4. | Incorrect |
We currently don’t have any vetted partners for this compound. Check back soon.
Side Effects and Safety Profile
Clinical Trial Safety Data
Phase I IV study (PMID: 20536472): Doses from 42 to 1,260 mg IV over 14 days. No dose-limiting toxicity. No serious adverse events. Phase I in Chinese volunteers: safe and well tolerated. Phase II/III ophthalmic: excellent local tolerability. 2025 cardiac RCT (n=96): No concerning signals at 90-day follow-up.
Reported Side Effects
Injection site redness (anecdotal, more common with TB-500 than Tβ4). Transient fatigue, headache, mild flu-like symptoms (anecdotal). Joint discomfort (anecdotal, rare).
Unknown Territory
Long-term use (>14 days systemic) not studied. Subcutaneous injection safety not established. Cancer risk with chronic use unresolved. Drug interactions not evaluated. Pregnancy, fertility, and pediatric effects unknown.
PLAIN ENGLISH
In the clinical trials that exist, Tβ4 appears safe in the short term — no serious side effects at doses up to 1,260 mg IV over two weeks. Eye drops were well tolerated. But “short-term safety in small trials” is not the same as “safe.”
Anti-Doping Status
Thymosin beta-4 and all its derivatives — including TB-500 — are prohibited at all times by the World Anti-Doping Agency under section S2.3 (Growth Factors and Growth Factor Modulators). The prohibition applies in-competition and out-of-competition.
Tβ4 was added as a named example under S2.3 in 2018 and is classified as a non-Specified Substance, meaning intentional use carries up to a four-year ban. Detection methods include mass spectrometry-based assays.
Notable case: The Cronulla Sharks (Australian NRL) were investigated in 2013 for administering Tβ4 to players during the 2011 season.
Legal and Regulatory Status
United States: Not FDA-approved. Category 2 bulk drug substance (compounding restricted since late 2023). February 2026 HHS announcement signals potential reclassification; formal notice not yet published. RGN-259 in active clinical development.
International: Not approved by EMA, TGA, Health Canada, or PMDA. Available from research chemical suppliers. Not a regulated pharmaceutical product.
Dosing and Administration
CRITICAL DISCLAIMER
The dosing information below is derived from published research and clinical trial protocols. No regulatory authority has established approved dosing for Tβ4 in any indication. Any use outside of clinical trials is not sanctioned by FDA, EMA, or equivalent bodies.
Published Clinical Dosing
Ophthalmic (RGN-259): 0.1% Tβ4 solution, one drop per eye, five times daily for 28 days. This is the only rigorously tested dosing regimen.
Intravenous (cardiac): Phase I used single IV doses of 42–1,260 mg, plus repeated daily doses at 420 and 1,260 mg for 14 days.
Community Protocols (Unvalidated)
COMMUNITY-SOURCED INFORMATION
The injectable dosing below is from community forums and dose extrapolation — not from clinical trials. No subcutaneous Tβ4 dose has been tested in humans. Do not self-administer without physician supervision.
Communities report subcutaneous injection of 2–5 mg, two to three times per week, in “loading” and “maintenance” phases. No published study has tested subcutaneous Tβ4 injection.
EDUCATIONAL NOTICE
The only validated human dosing exists for ophthalmic use and intravenous administration in hospital settings. The gap between these controlled settings and self-administered subcutaneous injection is a fundamental difference in safety monitoring, dose verification, and outcome measurement.
Peptide Preparation and Storage
Lyophilized: Store at –20°C for long-term; 2–8°C for short-term. Protect from light and moisture.
Reconstituted: Use bacteriostatic water. Store at 2–8°C, use within 21–28 days.
Stability: As a 43-amino-acid protein, Tβ4 is more susceptible to degradation than shorter peptides like BPC-157 (15 AA) or TB-500. Proper cold chain handling is essential. Avoid repeated freeze-thaw cycles.
Related Compounds: Side-by-Side Comparison
TB-500 vs. Tβ4: Fragment vs. parent. Different molecule, different evidence. TB-500 has zero human trials; Tβ4 has Phase I–III data.
BPC-157 vs. Tβ4: Different source (gastric juice vs. intracellular), different mechanism (growth factor upregulation vs. actin sequestration). BPC-157 has 3–5 small human studies; Tβ4 has more advanced clinical programs but in narrower indications.
GHK-Cu vs. Tβ4: GHK-Cu is a tripeptide with gene expression data; Tβ4 is a full protein with clinical trial data. Different scales of evidence, different mechanisms.
PRP vs. Tβ4: PRP is autologous, FDA-cleared for point-of-care use. Tβ4 is synthetic, not approved, with clinical data limited to ophthalmology and cardiology.
| Compound | Type | Primary Target | Half-Life | FDA Status | WADA Status | Evidence Tier | Primary Tissue Target | Route | Human Evidence Status | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|
| BPC-157 | Synthetic pentadecapeptide (15 amino acids, derived from gastric protective protein BPC) | VEGF / Nitric oxide (proposed multi-target) | ~2–6 hours | Not FDA-approved | Prohibited — S0 (Non-Approved Substances) | Tier 3 — Pilot / Limited Human Data | Musculoskeletal, tendon, ligament, GI tract, CNS | Subcutaneous injection + Oral (both routes studied) | 3 published human pilot studies (~30 subjects combined); no RCTs | Broadest tissue tropism in cluster. Only injury-repair peptide with both oral and injectable evidence. Most evidence in rodent models |
| TB-500 | Synthetic 4-amino-acid fragment (residues 17–23 of Thymosin Beta-4) | Actin binding (cell migration, angiogenesis) | ~2–3 hours | Not FDA-approved | Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) | Tier 4 — Preclinical Only | Musculoskeletal (muscle, tendon, ligament), cardiac, neurological | Subcutaneous injection | Zero published human clinical trials; animal models and cell culture only | Smallest fragment studied; synthetic derivative of endogenous Thymosin Beta-4. Actin sequestration may drive cell migration |
| Thymosin Beta-4 | Endogenous 43-amino-acid peptide (ubiquitous actin-sequestering protein) | Actin binding, cell migration, angiogenesis | ~2–4 hours | Not FDA-approved | Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) | Tier 3 — Pilot / Limited Human Data | Broad: muscle, cardiac, neurological, immune, epithelial | Subcutaneous injection + Topical (cosmetics) | Few human studies; cardiac regeneration in early-stage human data; cosmetic formulations | Full-length parent peptide of TB-500. Endogenous compound; ubiquitous in mammalian tissues. More potent than TB-500 fragment in vitro |
| GHK-Cu | Synthetic tripeptide-copper complex (Gly-His-Lys chelated to Cu2+) | Collagen synthesis, wound healing, TGF-beta modulation | ~2 hours topical; ~4–6 hours systemic (estimated) | Not FDA-approved (topical in cosmetics; injectable investigational) | Prohibited — S0 (injectable as growth factor analog); topical unregulated | Tier 5 — It's Complicated | Dermal (collagen, elastin remodeling); broad systemic effects proposed but unverified | Topical (cosmetics — extensive evidence) vs. Subcutaneous injection (preclinical only) | Topical: 30+ years cosmetic use data; Injectable: zero human trials | Route-dependent evidence: topical skin rejuvenation well-established, but injectable claims extrapolate from fundamentally different delivery |
| AHK-Cu | Synthetic copper tripeptide variant (Ala-His-Lys chelated to Cu2+) | Copper chelation, extracellular matrix remodeling, growth factor signaling | ~2–4 hours (estimated) | Not FDA-approved | Not WADA-listed | Tier 4 — Preclinical Only | Dermal (hair follicle, scalp), cosmetic | Topical (cosmetics) | No human clinical trials; in vitro and cosmetic formulation data only | GHK-Cu structural analog with alanine substitution. Primarily studied for hair growth. Less evidence base than GHK-Cu |
| LL-37 | Human cathelicidin antimicrobial peptide (37 amino acids) | Antimicrobial, wound healing, angiogenesis, vitamin D-regulated immune modulation | ~2–4 hours | Not FDA-approved | Not WADA-listed | Tier 3 — Pilot / Limited Human Data | Skin, mucosal surfaces, immune system | Subcutaneous injection, Topical | Limited human data; antimicrobial efficacy well-characterized in vitro; wound healing in animal models | Endogenous host defense peptide. Dual role: direct antimicrobial activity + immune modulation. Vitamin D pathway regulates expression |
| KPV | Alpha-MSH C-terminal tripeptide (Lys-Pro-Val) | NF-kB inhibition, anti-inflammatory (no melanocortin receptor activation) | ~1–2 hours (estimated) | Not FDA-approved | Not WADA-listed | Tier 4 — Preclinical Only | GI tract (colitis models), skin, immune system | Subcutaneous injection, Oral (investigational) | No published human clinical trials; animal models (colitis, dermatitis) only | Smallest anti-inflammatory peptide in cluster (3 amino acids). NF-kB pathway without melanocortin receptor binding. GI-focused research |
| VIP | Endogenous 28-amino-acid neuropeptide (vasoactive intestinal peptide) | VPAC1/VPAC2 receptor agonism; vasodilation, immunomodulation, bronchodilation | ~1–2 minutes (extremely short) | Not FDA-approved (aviptadil in clinical trials) | Not WADA-listed | Tier 2 — Clinical Trials | Pulmonary, GI tract, immune system, neurological | Subcutaneous injection, IV infusion, Intranasal | Multiple Phase 2 trials (ARDS, pulmonary hypertension, sarcoidosis); aviptadil in FDA pipeline | Shortest half-life in cluster. CIRS protocol use. Aviptadil (synthetic VIP) is furthest along FDA pathway among non-approved compounds here |
| KGF / Palifermin | Recombinant keratinocyte growth factor (FGF-7) | FGFR2b receptor; keratinocyte proliferation, epithelial barrier repair | ~3–5 hours | FDA-approved (Kepivance for oral mucositis) | Not WADA-listed | Tier 1 — Approved Drug | Epithelial surfaces (oral mucosa, GI tract, skin) | Intravenous injection (FDA-approved route) | FDA-approved for chemo-induced oral mucositis; multiple Phase 2/3 trials | Only FDA-approved compound in Cluster B. Specific to epithelial tissues. IV-only approved route limits off-label accessibility |
| Substance P | Endogenous 11-amino-acid tachykinin neuropeptide | NK1 receptor agonism; fibroblast migration, angiogenesis, immune activation | ~1–2 minutes | Not FDA-approved | Not WADA-listed | Tier 3 — Pilot / Limited Human Data | Corneal epithelium, skin, nervous system | Topical (corneal), Subcutaneous injection | Human data primarily in corneal wound healing; limited systemic human studies | Endogenous pain signaling peptide repurposed for tissue repair. Strongest human evidence in corneal healing. Dual role: nociception + repair |
| PRP | Autologous platelet-rich plasma (concentrated growth factor preparation) | PDGF, VEGF, TGF-beta release via platelet degranulation | N/A (not a single molecule) | FDA-cleared devices (not drug-approved) | Prohibited — M1 (Manipulation of Blood and Blood Components) | Tier 2 — Clinical Trials | Musculoskeletal (tendon, cartilage, bone), dermal, hair | Injection (local to injury site) | Hundreds of RCTs across orthopedic, dermatologic, and dental applications | Non-peptide. Autologous preparation — no synthetic manufacturing. Largest clinical evidence base in cluster but high study heterogeneity |
| ARA-290 | Synthetic 11-amino-acid peptide (cibinetide; EPO-derived tissue-protective peptide) | Innate Repair Receptor (EPOR/CD131 heterodimer) selective agonist | ~2–4 hours | Not FDA-approved (Phase 2b completed) | Not WADA-listed | Tier 2 — Clinical Trials | Peripheral nerves, retina, cardiac, immune system | Subcutaneous injection (1–8 mg daily in trials); IV infusion (early trials) | Phase 2b complete (sarcoidosis SFN — DOSARA trial); Phase 2 (diabetic neuropathy, diabetic macular edema) | EPO-derived but does NOT bind classical EPO receptor. No erythropoietic activity. Tissue protection without blood doping risk. Furthest clinical development for neuropathy |
Combination Protocols and the “Stacking” Question
COMMUNITY-SOURCED INFORMATION
The combination scenarios below are from community forums and theoretical pharmacology — not from clinical trials. No combination of Tβ4 with any other agent has been tested in a controlled study.
The “Wolverine stack” (Tβ4/TB-500 + BPC-157) is a staple of biohacking forums. The theoretical rationale is that BPC-157 and Tβ4 operate through complementary mechanisms (growth factor upregulation vs. actin-mediated cell migration). But complementary mechanisms in theory do not guarantee additive effects in practice.
The responsible position: using compounds one at a time provides clearer information about what is helping or hurting. Stacking introduces confounders that make attribution impossible.
Frequently Asked Questions
Is thymosin beta-4 the same as TB-500?
No. Thymosin beta-4 is a 43-amino-acid protein found naturally in the body. TB-500 is a synthetic fragment of that protein, typically corresponding to residues 17–23. They have different molecular weights, different structures, and different evidence bases. Clinical trials have been conducted with full-length Tβ4, not with TB-500.
Is thymosin beta-4 FDA-approved?
No. Tβ4 is not approved by the FDA for any indication. RGN-259 (a Tβ4 eye drop) is in clinical development for corneal conditions and dry eye, but no approval has been granted. The FDA classifies TB-500 as a Category 2 bulk drug substance, though this designation may change.
Does thymosin beta-4 cause cancer?
The evidence is mixed. Tβ4 promotes cell migration and angiogenesis, which are processes tumors also use. Some studies show pro-metastatic potential in tumor models; others show tumor-suppressive effects. Clinical trials have not reported cancer events, but they are short-duration and small-sample. Individuals with active malignancies should not use Tβ4 outside of clinical trials.
What is the evidence for thymosin beta-4 healing injuries?
The strongest human evidence is for corneal healing (Phase II/III trials with RGN-259 eye drops). Cardiac evidence includes a 2025 RCT in 96 STEMI patients that showed a positive signal but missed its primary endpoint. For musculoskeletal injuries — the application most people ask about — no controlled human trial exists. All tendon, ligament, and muscle healing evidence is from animal models.
Is thymosin beta-4 banned in sports?
Yes. WADA prohibits Tβ4 and all derivatives (including TB-500) at all times under section S2.3. It is classified as a non-Specified Substance, carrying the most severe penalties for a positive test.
What is the difference between Tβ4 and thymosin alpha-1?
They are structurally and functionally unrelated proteins that were both isolated from thymus tissue. Thymosin alpha-1 (Zadaxin) is an approved immunomodulatory drug in some countries. Tβ4 is an actin-sequestering protein involved in tissue repair. They share a historical naming convention, not a biological function.
Can I take thymosin beta-4 as an injection?
IV Tβ4 has been tested in clinical trials and appears safe at doses up to 1,260 mg over 14 days. Subcutaneous injection — the route used by most biohackers — has not been tested in any controlled human study. The safety and efficacy of self-administered subcutaneous Tβ4 injection are unknown.
How does thymosin beta-4 compare to BPC-157?
They operate through different mechanisms. BPC-157 upregulates growth factors and promotes angiogenesis via VEGF pathways. Tβ4 regulates actin dynamics to promote cell migration and vascular repair. BPC-157 has more animal studies but less advanced clinical programs. Tβ4 has Phase II/III ophthalmic trial data that BPC-157 lacks. Neither is clearly "better" — they target overlapping but distinct biological processes.
Is thymosin beta-4 natural?
Yes. Tβ4 is one of the most abundant proteins inside human cells. Your body produces it endogenously, with highest concentrations in platelets and wound fluid. The synthetic versions used in research and self-experimentation are recombinant copies of this natural protein. However, "natural" does not mean that exogenous administration replicates the effects of endogenous production — dose, timing, route, and context all matter.
What does "Tier 3" mean for thymosin beta-4?
Peptidings assigns evidence tiers to every compound. Tier 3 means "Pilot / Limited Human Data" — at least one published human study exists, but the evidence base is not yet sufficient for confident clinical conclusions. Tβ4 has multiple human studies (Phase I–III), which is more than many Tier 3 compounds, but the indications are narrow (eyes and cardiac) and no study has demonstrated the broad-spectrum healing effects that drive most consumer interest.
Summary of Key Findings
The ophthalmic evidence is the strongest. RGN-259 eye drops have been tested in two Phase II trials and one Phase III trial. Corneal healing, dry eye symptoms, and neurotrophic keratopathy all showed directional benefit with excellent safety.
The cardiac evidence is real but early. Two Phase I safety studies establish tolerability at high IV doses. The 2025 RCT in 96 STEMI patients shows a directional signal that missed its primary endpoint. This is a Phase II-level story, not a Phase III one.
Everything else is preclinical. Tendon repair, muscle healing, neuroprotection, hair growth, anti-aging — the applications that dominate online discussions have been studied exclusively in animal models.
The parent/fragment distinction is not academic. Tβ4 (43 amino acids) and TB-500 (7–17 amino acid fragment) are different molecules with different evidence bases. Every clinical trial used full-length Tβ4, not TB-500.
PLAIN ENGLISH
Tβ4 is a body-made repair protein with some real human trial data — mostly for eye problems and heart damage. But the things most people actually want it for — healing tendons, fixing injuries faster, slowing aging — have only been tested in animals. And the fragment version (TB-500) that most people actually buy has never been in a human trial at all. The biology is promising. The human evidence hasn’t caught up yet.
Verdict Recapitulation
Tβ4 earns “Reasonable Bet” because it clears a bar that most Cluster B compounds do not: it has been tested in randomized, controlled human trials. The ophthalmic and cardiac data — while narrow in scope and mixed in results — represent genuine clinical evidence. It does not earn “Strong Foundation” because no clinical program has reached definitive Phase III success, the most-discussed applications lack any human data, and the long-term safety profile remains unresolved.
Where to Source Thymosin Beta-4
Further Reading and Resources
If you want to go deeper on Thymosin Beta-4, the evidence landscape for tissue repair peptides, or our evaluation methodology.
On Peptidings
- TB-500 — The synthetic fragment of Tβ4. Different molecule, different evidence.
- BPC-157 — Complementary mechanism, the other half of the “Wolverine stack.”
- GHK-Cu — Copper peptide with topical evidence. Different mechanism entirely.
- Injury Recovery Research Hub — All Cluster B compounds compared.
- Evidence Framework — How we assign tiers and verdicts.
External Resources
- PubMed — Search “thymosin beta-4.”
- ClinicalTrials.gov — Registered trials.
Selected References and Key Studies
- Bock-Marquette I, Srivastava D et al. “Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration.” Ann NY Acad Sci. 2010. PubMed
- Srivastava D et al. “Thymosin beta4 is cardioprotective after myocardial infarction.” Ann NY Acad Sci. 2007. PubMed
- Hinkel R et al. “Cardioprotection by systemic dosing of thymosin beta four.” Front Pharmacol. 2013. PubMed
- Zhang J et al. “Thymosin β4 Protects against Cardiac Damage and Promotes Tissue Repair.” Int J Mol Sci. 2022. PubMed
- Dunn SP et al. “RGN-259 Phase II dry eye.” Clinical Ophthalmology. 2015. PubMed
- Sosne G et al. “Tβ4 Phase II severe dry eye.” Cornea. 2014. PubMed
- Sosne G et al. “RGN-259 Phase III neurotrophic keratopathy (SEER-1).” Transl Vis Sci Technol. 2022. PubMed
- Crockford D et al. “IV thymosin beta4 Phase I safety in healthy volunteers.” Ann NY Acad Sci. 2010. PubMed
- Li Y et al. “First-in-human recombinant human Tβ4 Phase I.” Front Pharmacol. 2021. PubMed
- Ye L et al. “Tβ4-pretreated EPC transplantation in STEMI.” J Cardiovasc Trans Res. 2016. PubMed
- Huff T et al. “β-Thymosins: small peptides with a long list of potential roles.” Trends Mol Med. 2005. PubMed
- Smart N et al. “Tβ4 does not reprogram epicardial cells into cardiomyocytes.” J Mol Cell Cardiol. 2012. PubMed
- Badamchian M et al. “Thymosin beta(4) reduces lethality from sepsis.” PMID: 12860178. Ann NY Acad Sci. 2003. PubMed
- Shah R et al. “Tβ4 limits inflammation through autophagy.” FASEB J. 2018. PubMed
- Goldstein AL et al. “Thymosin β4: actin-sequestering protein moonlights.” Cancer Metastasis Rev. 2003. PubMed
DISCLAIMER
The information presented in this article is for educational and research purposes only. Thymosin Beta-4 is not approved by the FDA for any indication in the United States. Nothing in this article constitutes medical advice. The clinical trials described were conducted under institutional oversight with safety monitoring that does not exist in self-administration contexts. Consult a qualified healthcare provider before making any decisions about peptide use.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 2, 2026 | Next scheduled review: July 2, 2026
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.